journal
https://read.qxmd.com/read/38632391/the-fasciola-cinereum-of-the-hippocampal-tail-as-an-interventional-target-in-epilepsy
#1
JOURNAL ARTICLE
Ryan M Jamiolkowski, Quynh-Anh Nguyen, Jordan S Farrell, Ryan J McGinn, David A Hartmann, Jeff J Nirschl, Mateo I Sanchez, Vivek P Buch, Ivan Soltesz
Targeted tissue ablation involving the anterior hippocampus is the standard of care for patients with drug-resistant mesial temporal lobe epilepsy. However, a substantial proportion continues to suffer from seizures even after surgery. We identified the fasciola cinereum (FC) neurons of the posterior hippocampal tail as an important seizure node in both mice and humans with epilepsy. Genetically defined FC neurons were highly active during spontaneous seizures in epileptic mice, and closed-loop optogenetic inhibition of these neurons potently reduced seizure duration...
April 17, 2024: Nature Medicine
https://read.qxmd.com/read/38627562/placental-igfbp1-levels-during-early-pregnancy-and-the-risk-of-insulin-resistance-and-gestational-diabetes
#2
JOURNAL ARTICLE
Marie-France Hivert, Frédérique White, Catherine Allard, Kaitlyn James, Sana Majid, François Aguet, Kristin G Ardlie, Jose C Florez, Andrea G Edlow, Luigi Bouchard, Pierre-Étienne Jacques, S Ananth Karumanchi, Camille E Powe
Reduced insulin sensitivity (insulin resistance) is a hallmark of normal physiology in late pregnancy and also underlies gestational diabetes mellitus (GDM). We conducted transcriptomic profiling of 434 human placentas and identified a positive association between insulin-like growth factor binding protein 1 gene (IGFBP1) expression in the placenta and insulin sensitivity at ~26 weeks gestation. Circulating IGFBP1 protein levels rose over the course of pregnancy and declined postpartum, which, together with high gene expression levels in our placenta samples, suggests a placental or decidual source...
April 16, 2024: Nature Medicine
https://read.qxmd.com/read/38627561/nicotine-e-cigarettes-considerations-for-healthcare-providers
#3
LETTER
Benjamin A Toll, Tracy T Smith, Brian A King
No abstract text is available yet for this article.
April 16, 2024: Nature Medicine
https://read.qxmd.com/read/38627560/transparent-medical-image-ai-via-an-image-text-foundation-model-grounded-in-medical-literature
#4
JOURNAL ARTICLE
Chanwoo Kim, Soham U Gadgil, Alex J DeGrave, Jesutofunmi A Omiye, Zhuo Ran Cai, Roxana Daneshjou, Su-In Lee
Building trustworthy and transparent image-based medical artificial intelligence (AI) systems requires the ability to interrogate data and models at all stages of the development pipeline, from training models to post-deployment monitoring. Ideally, the data and associated AI systems could be described using terms already familiar to physicians, but this requires medical datasets densely annotated with semantically meaningful concepts. In the present study, we present a foundation model approach, named MONET (medical concept retriever), which learns how to connect medical images with text and densely scores images on concept presence to enable important tasks in medical AI development and deployment such as data auditing, model auditing and model interpretation...
April 16, 2024: Nature Medicine
https://read.qxmd.com/read/38627559/prediction-of-tumor-origin-in-cancers-of-unknown-primary-origin-with-cytology-based-deep-learning
#5
JOURNAL ARTICLE
Fei Tian, Dong Liu, Na Wei, Qianqian Fu, Lin Sun, Wei Liu, Xiaolong Sui, Kathryn Tian, Genevieve Nemeth, Jingyu Feng, Jingjing Xu, Lin Xiao, Junya Han, Jingjie Fu, Yinhua Shi, Yichen Yang, Jia Liu, Chunhong Hu, Bin Feng, Yan Sun, Yunjun Wang, Guohua Yu, Dalu Kong, Meiyun Wang, Wencai Li, Kexin Chen, Xiangchun Li
Cancer of unknown primary (CUP) site poses diagnostic challenges due to its elusive nature. Many cases of CUP manifest as pleural and peritoneal serous effusions. Leveraging cytological images from 57,220 cases at four tertiary hospitals, we developed a deep-learning method for tumor origin differentiation using cytological histology (TORCH) that can identify malignancy and predict tumor origin in both hydrothorax and ascites. We examined its performance on three internal (n = 12,799) and two external (n = 14,538) testing sets...
April 16, 2024: Nature Medicine
https://read.qxmd.com/read/38627558/a-framework-for-implementing-patient-reported-outcomes-in-clinical-care-the-proteus-practice-guide
#6
LETTER
Norah L Crossnohere, Nicola Anderson, Judith Baumhauer, Melanie Calvert, Rebecca Esparza, Sandi Gulbransen, Lotte Haverman, Yuchen Li, Carolyn Petersen, Ameeta Retzer, Christopher Sidey-Gibbons, Angela M Stover, Elissa Thorner, Garrett Ursin, Galina Velikova, Elliott Sparkman Walker, Michael Brundage, Claire Snyder
No abstract text is available yet for this article.
April 16, 2024: Nature Medicine
https://read.qxmd.com/read/38622250/author-correction-continuous-glucose-monitoring-and-intrapersonal-variability-in-fasting-glucose
#7
Smadar Shilo, Ayya Keshet, Hagai Rossman, Anastasia Godneva, Yeela Talmor-Barkan, Yaron Aviv, Eran Segal
No abstract text is available yet for this article.
April 15, 2024: Nature Medicine
https://read.qxmd.com/read/38622249/prasinezumab-slows-motor-progression-in-rapidly-progressing-early-stage-parkinson-s-disease
#8
JOURNAL ARTICLE
Gennaro Pagano, Kirsten I Taylor, Judith Anzures Cabrera, Tanya Simuni, Kenneth Marek, Ronald B Postuma, Nicola Pavese, Fabrizio Stocchi, Kathrin Brockmann, Hanno Svoboda, Dylan Trundell, Annabelle Monnet, Rachelle Doody, Paulo Fontoura, Geoffrey A Kerchner, Patrik Brundin, Tania Nikolcheva, Azad Bonni
Prasinezumab, a monoclonal antibody that binds aggregated α-synuclein, is being investigated as a potential disease-modifying therapy in early-stage Parkinson's disease. Although in the PASADENA phase 2 study, the primary endpoint (Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) sum of Parts I + II + III) was not met, prasinezumab-treated individuals exhibited slower progression of motor signs than placebo-treated participants (MDS-UPDRS Part III)...
April 15, 2024: Nature Medicine
https://read.qxmd.com/read/38609515/designer-antibiotics-by-generative-ai
#9
Karen O'Leary
No abstract text is available yet for this article.
April 12, 2024: Nature Medicine
https://read.qxmd.com/read/38605167/why-diversity-is-needed-at-every-level-of-clinical-trials-from-participants-to-leaders
#10
JOURNAL ARTICLE
Khadijah Breathett
No abstract text is available yet for this article.
April 11, 2024: Nature Medicine
https://read.qxmd.com/read/38605166/feasibility-of-functional-precision-medicine-for-guiding-treatment-of-relapsed-or-refractory-pediatric-cancers
#11
JOURNAL ARTICLE
Arlet M Acanda De La Rocha, Noah E Berlow, Maggie Fader, Ebony R Coats, Cima Saghira, Paula S Espinal, Jeanette Galano, Ziad Khatib, Haneen Abdella, Ossama M Maher, Yana Vorontsova, Cristina M Andrade-Feraud, Aimee Daccache, Alexa Jacome, Victoria Reis, Baylee Holcomb, Yasmin Ghurani, Lilliam Rimblas, Tomás R Guilarte, Nan Hu, Daria Salyakina, Diana J Azzam
Children with rare, relapsed or refractory cancers often face limited treatment options, and few predictive biomarkers are available that can enable personalized treatment recommendations. The implementation of functional precision medicine (FPM), which combines genomic profiling with drug sensitivity testing (DST) of patient-derived tumor cells, has potential to identify treatment options when standard-of-care is exhausted. The goal of this prospective observational study was to generate FPM data for pediatric patients with relapsed or refractory cancer...
April 11, 2024: Nature Medicine
https://read.qxmd.com/read/38605165/functional-precision-medicine-for-pediatric-cancers
#12
JOURNAL ARTICLE
M Emmy M Dolman, Paul G Ekert
No abstract text is available yet for this article.
April 11, 2024: Nature Medicine
https://read.qxmd.com/read/38600282/generative-models-improve-fairness-of-medical-classifiers-under-distribution-shifts
#13
JOURNAL ARTICLE
Ira Ktena, Olivia Wiles, Isabela Albuquerque, Sylvestre-Alvise Rebuffi, Ryutaro Tanno, Abhijit Guha Roy, Shekoofeh Azizi, Danielle Belgrave, Pushmeet Kohli, Taylan Cemgil, Alan Karthikesalingam, Sven Gowal
Domain generalization is a ubiquitous challenge for machine learning in healthcare. Model performance in real-world conditions might be lower than expected because of discrepancies between the data encountered during deployment and development. Underrepresentation of some groups or conditions during model development is a common cause of this phenomenon. This challenge is often not readily addressed by targeted data acquisition and 'labeling' by expert clinicians, which can be prohibitively expensive or practically impossible because of the rarity of conditions or the available clinical expertise...
April 10, 2024: Nature Medicine
https://read.qxmd.com/read/38600260/-inverse-vaccines-could-treat-autoimmune-disease-from-multiple-sclerosis-to-celiac-disease
#14
Carrie Arnold
No abstract text is available yet for this article.
April 10, 2024: Nature Medicine
https://read.qxmd.com/read/38589604/tackling-heat-related-mortality-in-aging-populations
#15
JOURNAL ARTICLE
Josiah L Kephart, Safiyyah M Okoye
No abstract text is available yet for this article.
April 8, 2024: Nature Medicine
https://read.qxmd.com/read/38589603/food-is-medicine-clinical-trials-show-the-health-benefits-of-dietary-interventions
#16
Priya Venkatesan
No abstract text is available yet for this article.
April 8, 2024: Nature Medicine
https://read.qxmd.com/read/38589602/continuous-glucose-monitoring-and-intrapersonal-variability-in-fasting-glucose
#17
JOURNAL ARTICLE
Smadar Shilo, Ayya Keshet, Hagai Rossman, Anastasia Godneva, Yeela Talmor-Barkan, Yaron Aviv, Eran Segal
Plasma fasting glucose (FG) levels play a pivotal role in the diagnosis of prediabetes and diabetes worldwide. Here we investigated FG values using continuous glucose monitoring (CGM) devices in nondiabetic adults aged 40-70 years. FG was measured during 59,565 morning windows of 8,315 individuals (7.16 ± 3.17 days per participant). Mean FG was 96.2 ± 12.87 mg dl-1 , rising by 0.234 mg dl-1 per year with age. Intraperson, day-to-day variability expressed as FG standard deviation was 7...
April 8, 2024: Nature Medicine
https://read.qxmd.com/read/38589601/maternal-diabetes-and-risk-of-attention-deficit-hyperactivity-disorder-in-offspring-in-a-multinational-cohort-of-3-6-million-mother-child-pairs
#18
JOURNAL ARTICLE
Adrienne Y L Chan, Le Gao, Miyuki Hsing-Chun Hsieh, Lars J Kjerpeseth, Raquel Avelar, Tobias Banaschewski, Amy Hai Yan Chan, David Coghill, Jacqueline M Cohen, Mika Gissler, Jeff Harrison, Patrick Ip, Øystein Karlstad, Wallis C Y Lau, Maarit K Leinonen, Wing Cheong Leung, Tzu-Chi Liao, Johan Reutfors, Shih-Chieh Shao, Emily Simonoff, Kathryn Choon Beng Tan, Katja Taxis, Andrew Tomlin, Carolyn E Cesta, Edward Chia-Cheng Lai, Helga Zoega, Kenneth K C Man, Ian C K Wong
Previous studies report an association between maternal diabetes mellitus (MDM) and attention-deficit/hyperactivity disorder (ADHD), often overlooking unmeasured confounders such as shared genetics and environmental factors. We therefore conducted a multinational cohort study with linked mother-child pairs data in Hong Kong, New Zealand, Taiwan, Finland, Iceland, Norway and Sweden to evaluate associations between different MDM (any MDM, gestational diabetes mellitus (GDM) and pregestational diabetes mellitus (PGDM)) and ADHD using Cox proportional hazards regression...
April 8, 2024: Nature Medicine
https://read.qxmd.com/read/38584166/personalized-neoantigen-vaccine-and-pembrolizumab-in-advanced-hepatocellular-carcinoma-a-phase-1-2-trial
#19
JOURNAL ARTICLE
Mark Yarchoan, Edward J Gane, Thomas U Marron, Renzo Perales-Linares, Jian Yan, Neil Cooch, Daniel H Shu, Elana J Fertig, Luciane T Kagohara, Gabor Bartha, Josette Northcott, John Lyle, Sarah Rochestie, Joann Peters, Jason T Connor, Elizabeth M Jaffee, Ildiko Csiki, David B Weiner, Alfredo Perales-Puchalt, Niranjan Y Sardesai
Programmed cell death protein 1 (PD-1) inhibitors have modest efficacy as a monotherapy in hepatocellular carcinoma (HCC). A personalized therapeutic cancer vaccine (PTCV) may enhance responses to PD-1 inhibitors through the induction of tumor-specific immunity. We present results from a single-arm, open-label, phase 1/2 study of a DNA plasmid PTCV (GNOS-PV02) encoding up to 40 neoantigens coadministered with plasmid-encoded interleukin-12 plus pembrolizumab in patients with advanced HCC previously treated with a multityrosine kinase inhibitor...
April 7, 2024: Nature Medicine
https://read.qxmd.com/read/38580817/author-correction-a-fluid-biomarker-reveals-loss-of-tdp-43-splicing-repression-in-presymptomatic-als-ftd
#20
Katherine E Irwin, Pei Jasin, Kerstin E Braunstein, Irika R Sinha, Mark A Garret, Kyra D Bowden, Koping Chang, Juan C Troncoso, Abhay Moghekar, Esther S Oh, Denitza Raitcheva, Dan Bartlett, Timothy Miller, James D Berry, Bryan J Traynor, Jonathan P Ling, Philip C Wong
No abstract text is available yet for this article.
April 5, 2024: Nature Medicine
journal
journal
32162
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.